stockrow
Friday 6 November 2026
Export GLAS’s income statement to Excel — free account
Glass House Brands Inc.
GLAS Healthcare Drug Manufacturers Specialty & Generic
Glass House Brands Inc.’s revenue for fiscal 2025 (year ended December 2025) was $182.0 million, down 9.41% from fiscal 2024.
- Revenue
- −1.24%
- EPS
- −320.0%
- Free cash flow
- −123.4%
- Total debt
- −17.2%
Quarter to June 2026, against a year earlier
2.28
0.30
−11.63%
Follow GLAS
Alert me
| Dec '25 | Dec '24 | Dec '23 | |
|---|---|---|---|
Piotroski F-Score |
3 | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 |
P/S ratio |
3.98 | 2.17 | 0.00 |
Altman Z-Score |
1.39 | 0.97 | (0.18) |
P/FCF ratio |
0.00 | 24.11 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(1.62) | (1.53) | (3.67) |
Beneish M-Score |
(3.38) | (2.25) | — |
P/Operating CF |
(195.93) | 53.26 | (331.65) |
P/B ratio |
8.83 | 5.62 | 0.00 |
Price to Tangible BV |
8.92 | 6.87 | 0.00 |
EV/Sales |
4.30 | 2.25 | 0.00 |
EV/EBITDA |
0.00 | 21.73 | 0.00 |
EV/Operating CF |
68.29 | 15.91 | 0.00 |
EV/FCF |
(50.40) | 24.96 | 0.00 |
Quick Ratio |
0.66 | 0.66 | 0.42 |
Current Ratio |
1.78 | 0.99 | 0.56 |
Net Debt/EBITDA |
(64.84) | 0.74 | (0.73) |
Debt/Assets |
21.88% | 16.82% | 19.10% |
Debt/Equity |
0.85 | 0.67 | 0.87 |
Asset Turnover |
0.58 | 0.65 | 0.00 |
Operating CF/Net income |
(0.25) | (1.84) | (0.20) |
Capex/Depreciation |
(1.71) | (0.68) | (0.84) |
Interest Coverage |
(2.34) | 0.62 | (5.04) |
| (56.40%) | (21.33%) | 0.00% | |
| (14.33%) | (5.03%) | 0.00% | |
ROIC |
(7.83%) | 3.86% | (33.43%) |
Return on Tangible Assets |
(17.43%) | (7.29%) | (65.74%) |
Average Days of Receivables |
10.45 | 12.99 | 9.03 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
36.69% | 31.13% | 34.66% |
Intangible Assets out of Total Assets |
0.04 | 0.05 | 0.07 |
Share Based Compensation of Revenue |
7.36% | 6.52% | 4.75% |
Graham Net Nets |
(0.23) | (0.38) | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 |
Earnings Yield |
(6.21%) | (3.62%) | (3.62%) |
Free Cash Flow Yield |
(2.14%) | 4.15% | 0.00% |
Revenue per Share |
2.22 | 2.67 | 2.23 |
Operating CF per Share |
0.14 | 0.38 | 0.32 |
Capex per Share |
(0.33) | (0.14) | (0.17) |
Free Cash Flow per Share |
(0.19) | 0.24 | 0.15 |
Cash per Share |
0.24 | 0.49 | 0.45 |
Shareholders Equity per Share |
1.00 | 1.03 | 0.93 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
1.00 | 1.03 | 0.93 |
Free Cash Flow |
(15.51) | 18.10 | 10.92 |
Working Capital |
29.79 | (0.38) | (38.14) |
Capital Expenditures |
(26.96) | (10.29) | (12.31) |
Net Current Asset Value |
(168.71) | (166.71) | (187.48) |
EV/EBIT |
0.00 | 78.73 | 0.00 |
Capex to Sales |
0.15 | 0.05 | 0.08 |
Price to Operating Income |
0.00 | 76.06 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
0.07 | 0.07 | 0.07 |
Cash ROIC |
(9.03%) | 10.85% | 6.92% |
Accounts Receivable Turnover |
29.45 | 36.10 | 0.00 |
Accounts Payable Turnover |
3.13 | 3.57 | 0.00 |
Inventory Turnover |
5.19 | 8.96 | 0.00 |
Average Days of Payables |
125.01 | 109.77 | 123.08 |
Days of Inventory on Hand |
91.15 | 50.26 | 40.40 |
Average Receivables |
6.18 | 5.56 | — |
Average Payables |
33.55 | 29.03 | — |
Average Inventory |
20.24 | 11.55 | — |
Average Assets |
314.53 | 307.14 | — |
Average Common Equity |
79.90 | 72.39 | — |
Columns are period end dates · fundamentals updated 2 Nov 2026